理解抗癌药物的脑穿透性。
Understanding brain penetrance of anticancer drugs.
机构信息
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Neurosurgery, UCSF Medical School, San Francisco, California.
出版信息
Neuro Oncol. 2018 Apr 9;20(5):589-596. doi: 10.1093/neuonc/noy018.
Abstract
This paper explicates the impact of tumor capillary permeability for glioma World Health Organization (WHO) grades II to IV on brain-penetrant drug entry and distribution within the tumor and the brain adjacent to tumor (leading edge). In addition, we consider the distribution of non-brain penetrant drugs and how, in some cases, large-molecular-weight drugs might achieve good distribution into tumor and brain adjacent to tumor.
摘要
本文阐述了肿瘤毛细血管通透性对世界卫生组织（WHO）分级 II 至 IV 级脑胶质瘤的影响，包括药物进入肿瘤和肿瘤邻近脑区（前沿）的分布情况。此外，我们还考虑了非脑渗透药物的分布情况，以及在某些情况下，大分子量药物如何能够很好地分布到肿瘤和肿瘤邻近脑区。
相似文献
1
Understanding brain penetrance of anticancer drugs.理解抗癌药物的脑穿透性。
Neuro Oncol. 2018 Apr 9;20(5):589-596. doi: 10.1093/neuonc/noy018.
2
[Temporary hyperosmolar breakage of the blood-brain barrier improves effectiveness of chemotherapy for cerebral tumors].[血脑屏障的暂时性高渗性破坏可提高脑肿瘤化疗的疗效]
Zh Vopr Neirokhir Im N N Burdenko. 2008 Jul-Sep(3):52-9.
3
Effect of intracarotid infusion of etoposide: modification of the permeability of the blood-brain barrier and the blood-tumor barrier in rat brain tumor model.颈内动脉输注依托泊苷的效果：大鼠脑肿瘤模型中血脑屏障和血肿瘤屏障通透性的改变
Acta Med Okayama. 1999 Feb;53(1):5-11. doi: 10.18926/AMO/31645.
4
Enhancement in blood-tumor barrier permeability and delivery of liposomal doxorubicin using focused ultrasound and microbubbles: evaluation during tumor progression in a rat glioma model.使用聚焦超声和微泡增强血肿瘤屏障通透性及脂质体阿霉素递送：大鼠胶质瘤模型肿瘤进展过程中的评估
Phys Med Biol. 2015 Mar 21;60(6):2511-27. doi: 10.1088/0031-9155/60/6/2511. Epub 2015 Mar 6.
5
Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study.全脑放疗未能提高脑转移非小细胞肺癌患者的脑内吉非替尼浓度：一项自我对照的初步研究。
Cancer Chemother Pharmacol. 2015 Oct;76(4):873-7. doi: 10.1007/s00280-015-2847-z. Epub 2015 Aug 27.
6
Capillary permeability in experimental rat glioma and effects of intracarotid CDDP administration on tumor drug delivery.实验性大鼠胶质瘤中的毛细血管通透性及颈内动脉注射顺铂对肿瘤药物递送的影响
J Neurooncol. 1993 Jun;16(3):211-5. doi: 10.1007/BF01057035.
7
The effect of graded hypertonic intracarotid infusions on drug delivery to experimental RG-2 gliomas.分级高渗颈内动脉输注对实验性RG-2胶质瘤药物递送的影响。
Neurology. 1984 Dec;34(12):1571-81. doi: 10.1212/wnl.34.12.1571.
8
How to Make Anticancer Drugs Cross the Blood-Brain Barrier to Treat Brain Metastases.如何让抗癌药物穿越血脑屏障治疗脑转移。
Int J Mol Sci. 2019 Dec 18;21(1):22. doi: 10.3390/ijms21010022.
9
Inducing a Transient Increase in Blood-Brain Barrier Permeability for Improved Liposomal Drug Therapy of Glioblastoma Multiforme.诱导血脑屏障通透性短暂增加以改善多形性胶质母细胞瘤的脂质体药物治疗。
ACS Nano. 2019 Jan 22;13(1):97-113. doi: 10.1021/acsnano.8b03785. Epub 2018 Dec 19.
10
Calcium-dependent potassium channels as a target protein for modulation of the blood-brain tumor barrier.钙依赖性钾通道作为调节血脑肿瘤屏障的靶蛋白。
Drug News Perspect. 2003 Jun;16(5):291-8. doi: 10.1358/dnp.2003.16.5.878815.
引用本文的文献
1
Assessing the dose of regadenoson required to transiently alter blood-brain barrier integrity in patients with infiltrating gliomas.评估在浸润性胶质瘤患者中短暂改变血脑屏障完整性所需的瑞加诺生剂量。
Neurooncol Adv. 2025 Feb 15;7(1):vdaf041. doi: 10.1093/noajnl/vdaf041. eCollection 2025 Jan-Dec.
2
Disulfidptosis as a key regulator of glioblastoma progression and immune cell impairment.二硫化物诱导的细胞死亡作为胶质母细胞瘤进展和免疫细胞损伤的关键调节因子。
Front Immunol. 2025 Jan 30;16:1526296. doi: 10.3389/fimmu.2025.1526296. eCollection 2025.
3
Synergistic Anti-Cancer Effects of Isocnicin and Radiotherapy in Glioblastoma: A Natural Compound's Potential.异烟肼与放疗对胶质母细胞瘤的协同抗癌作用：一种天然化合物的潜力
Biomedicines. 2024 Dec 9;12(12):2793. doi: 10.3390/biomedicines12122793.
4
Natural Compounds and Cancer: Current Evidences.天然化合物与癌症：当前证据
Maedica (Bucur). 2024 Sep;19(3):621-628. doi: 10.26574/maedica.2024.19.3.621.
5
The Three Pillars of Glioblastoma: A Systematic Review and Novel Analysis of Multi-Omics and Clinical Data.胶质母细胞瘤的三支柱：多组学和临床数据的系统评价及新分析。
Cells. 2024 Oct 23;13(21):1754. doi: 10.3390/cells13211754.
6
Determination of Pralsetinib in Human Plasma and Cerebrospinal Fluid for Therapeutic Drug Monitoring by Ultra-performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS).采用超高效液相色谱-串联质谱法（UPLC-MS/MS）测定人血浆和脑脊液中普拉替尼的浓度用于治疗药物监测。
Anticancer Agents Med Chem. 2024;24(11):867-877. doi: 10.2174/0118715206290110240326071909.
7
Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non-small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study.表皮生长因子受体突变非小细胞肺癌伴脑转移患者奥希替尼的脑暴露：一项正电子发射断层扫描和磁共振成像研究。
Clin Transl Sci. 2023 Jun;16(6):955-965. doi: 10.1111/cts.13500. Epub 2023 Mar 15.
8
Siderol Inhibits Proliferation of Glioblastoma Cells and Acts Synergistically with Temozolomide.铁调素抑制胶质母细胞瘤细胞增殖并与替莫唑胺协同作用。
Biomedicines. 2022 Dec 12;10(12):3216. doi: 10.3390/biomedicines10123216.
9
Expression of hub genes of endothelial cells in glioblastoma-A prognostic model for GBM patients integrating single-cell RNA sequencing and bulk RNA sequencing.内皮细胞枢纽基因在胶质母细胞瘤中的表达——整合单细胞 RNA 测序和批量 RNA 测序的 GBM 患者预后模型。
BMC Cancer. 2022 Dec 6;22(1):1274. doi: 10.1186/s12885-022-10305-z.
10
Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies.在分子靶向和免疫治疗时代，高级别脑胶质瘤在早期药物开发过程中的治疗反应评估。
Cancer J. 2021;27(5):395-403. doi: 10.1097/PPO.0000000000000543.
本文引用的文献
1
Challenges of developing small-molecule kinase inhibitors for brain tumors and the need for emphasis on free drug levels.开发用于脑肿瘤的小分子激酶抑制剂的挑战，以及需要强调游离药物水平。
Neuro Oncol. 2018 Feb 19;20(3):307-312. doi: 10.1093/neuonc/nox179.
2
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.ABT-414 联合放疗和替莫唑胺治疗新诊断胶质母细胞瘤的疗效和安全性结果。
Neuro Oncol. 2017 Jul 1;19(7):965-975. doi: 10.1093/neuonc/now257.
3
ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.ABT-414，一种靶向肿瘤选择性表皮生长因子受体（EGFR）表位的抗体药物偶联物。
Mol Cancer Ther. 2016 Apr;15(4):661-9. doi: 10.1158/1535-7163.MCT-15-0901. Epub 2016 Feb 4.
4
CNS Anticancer Drug Discovery and Development Conference White Paper.中枢神经系统抗癌药物发现与开发会议白皮书。
Neuro Oncol. 2015 Nov;17 Suppl 6(Suppl 6):vi1-26. doi: 10.1093/neuonc/nov169.
5
Glioma grading by microvascular permeability parameters derived from dynamic contrast-enhanced MRI and intratumoral susceptibility signal on susceptibility weighted imaging.通过动态对比增强磁共振成像得出的微血管通透性参数以及磁敏感加权成像上的瘤内磁化率信号对神经胶质瘤进行分级。
Cancer Imaging. 2015 Mar 21;15(1):4. doi: 10.1186/s40644-015-0039-z.
6
Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.人源化肿瘤特异性抗表皮生长因子受体单克隆抗体ABT-806的特性研究
Mol Cancer Ther. 2015 May;14(5):1141-51. doi: 10.1158/1535-7163.MCT-14-0820. Epub 2015 Mar 2.
7
CNS drug design: balancing physicochemical properties for optimal brain exposure.中枢神经系统药物设计：平衡理化性质以实现最佳脑内暴露。
J Med Chem. 2015 Mar 26;58(6):2584-608. doi: 10.1021/jm501535r. Epub 2015 Jan 6.
8
Lead- and drug-like compounds: the rule-of-five revolution.类铅化合物和类药物化合物：五规则革命
Drug Discov Today Technol. 2004 Dec;1(4):337-41. doi: 10.1016/j.ddtec.2004.11.007.
9
Relationship of octanol/water partition coefficient and molecular weight to cellular permeability and partitioning in s49 lymphoma cells.辛醇/水分配系数和分子量与 S49 淋巴瘤细胞的细胞通透性和分配的关系。
Pharm Res. 1984 Nov;1(6):259-66. doi: 10.1023/A:1016393902123.
10
Low-grade and anaplastic oligodendrogliomas: differences in tumour microvascular permeability evaluated with dynamic contrast-enhanced magnetic resonance imaging.低级别和间变性少突胶质细胞瘤：动态对比增强磁共振成像评估的肿瘤微血管通透性差异。
J Clin Neurosci. 2013 Aug;20(8):1110-3. doi: 10.1016/j.jocn.2012.09.019. Epub 2013 May 11.
Zotero 插件